Aim. To study pharmacokinetics of liposomal daunorubicine DaunoXome and dau
norubicine (rubomycin) associated with red cells; to assess their effective
ness and toxicity in patients with acute leukemia.
Materials and methods. 7 patients with resistant or recurrent acute leukemi
a entered the trial. Of them 2 patients had acute myeloid leukemia. They re
ceived DaunoXome in dose 100 mg in days 1, 2 and 3 of 7+3 program. 1 patien
t had pretreated acute promyelocytic leukemia. This patient received 5-day
course of DaunoXome in a dose 100 mg in the presence of ATRA therapy. 4 pat
ients were given single dose daunorubicin associated with autoerythrocytes
in the courses RACOP and 7+3 in a dose 45 mg/m(2). Concentrations of free,
bound and liposomal daunorubicin were determined spectrofluorimetrically in
chlorophorm extracts of plasm, blood, liquor and bone marrow specimens.
Results. Immobilization of daunorubicin on the red cells and liposomes chan
ges pharmacokinetics of the drug: peak concentrations change and the area u
nder the concentration curve increases. Tolerance of DaunoXome and daunorub
icine associated with red cells was satisfactory in all the cases: clinical
and echo-CG signs of cardiotoxicity were absent, myelotoxicity was similar
to that of free daunorubicine. DaunoXome was effective in 2 of 3 patients
with acute myeloblastic leukemia.
Conclusion. The findings are of practical interest for physicians designing
new programs of therapy of acute leukemia.